专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5393765A Pharmaceutical compositions with constant erosion volume for zero order controlled release 失效
标题翻译：具有恒定侵蚀体积的药物组合物，用于零级控制释放
公开(公告)号：US5393765A
公开(公告)日：1995-02-28
申请号：US166123
申请日：1993-12-13
申请人： Martin H. Infeld , A. Waseem Malick , Navnit H. Shah , Wantanee Phuapradit
发明人： Martin H. Infeld , A. Waseem Malick , Navnit H. Shah , Wantanee Phuapradit
IPC分类号： A61K9/20 , A61K9/22 , A61K31/425 , A61K47/38 , A61K47/00
CPC分类号： A61K31/425 , A61K9/2018 , A61K9/2054
摘要： An erodible pharmaceutical composition providing a unique zero order controlled release profile is herein described. The erodible composition contains a therapeutically active substance having a solubility not greater than 80 mg/mL, a hydroxypropyl methylcellulose derivative and erosion modifiers depending on drug solubility and drug loading, such as lactose and polyoxyalkylene derivatives of propylene glycol, as well as other inert materials such as binders and lubricants. The hydroxypropyl methylcellulose derivative is most preferably a hydroxy-propylmethyl having a methoxy content of about 19-30% and hydroxypropyl content of 7-12%, a methoxy degree of substitution from 1.1 to 2.0, a molecular weight of approximately 20,000 to 26,000 daltons and a viscosity of a 2% w/w polymer solution at 25.degree. C. ranging from 50 to 100 cps. The composition erodes with a constant erosion volume for a desired time period. When ingested, the matrix forms two layers, an outer layer of hydrated matrix which is eroding and an inner core of unchanged matrix. The composition provides a zero order release profile in part because the diffusion rate of the drug from the matrix is either negligible or is comparable to the erosion rate of the matrix and the drug concentration in the hydrated layer remains constant.
摘要翻译：这里描述了提供独特的零级控制释放曲线的可侵蚀的药物组合物。可溶性组合物含有不大于80mg / mL的溶解度的治疗活性物质，羟丙基甲基纤维素衍生物和取决于药物溶解度和药物负荷的侵蚀改性剂，例如丙二醇的乳糖和聚氧化烯衍生物以及其它惰性物质如粘合剂和润滑剂。羟丙基甲基纤维素衍生物最优选甲氧基含量为约19-30％，羟丙基含量为7-12％，甲氧基取代度为1.1至2.0，分子量为约20,000至26,000道尔顿的羟基丙基甲基和 25℃下2％w / w聚合物溶液的粘度为50至100cps。组合物以恒定的侵蚀体积侵蚀所需时间段。当摄取时，基质形成两层，即水分基质的外层是侵蚀的，内层是不变的基体。该组合物提供了零级释放曲线，部分原因是药物从基质的扩散速率可以忽略不计，或与基质的侵蚀速度相当，并且水合层中的药物浓度保持恒定。

2. 发明授权

US5190748A Absorption enhancement of antibiotics 失效
标题翻译：抗生素吸收增强
公开(公告)号：US5190748A
公开(公告)日：1993-03-02
申请号：US809244
申请日：1991-12-18
申请人： Maria O. Bachynsky , Martin H. Infeld , Navnit Shah , Joel Unowsky
发明人： Maria O. Bachynsky , Martin H. Infeld , Navnit Shah , Joel Unowsky
IPC分类号： A61K9/48 , A61K47/10 , A61K47/12 , A61K47/14
CPC分类号： A61K47/14 , A61K47/10 , A61K47/12 , A61K9/4858 , Y10S514/946 , Y10S514/947
摘要： The absorption of antibiotics given through oral and rectal routes of administration is significantly enhanced by use of the antibiotic in conjunction with a two-component absorption enhancing system made up of an ether of a C.sub.6 to C.sub.18 alcohol and a polyoxyethylene glycol together with a second component selected from among polyoxyethylene glycol C.sub.6 to C.sub.18 glyceride esters, C.sub.6 to C.sub.18 carboxylic acids or salts thereof, and esters of two or more C.sub.6 to C.sub.18 carboxylic acids, glycerol and a polyoxyethylene glycol. A carrier and adjuvants are usually included. These compositions can be administered in any convenient oral or rectal dosage form, including tablets, capsules, beadlets and suppositories.
摘要翻译：通过口服和直肠给药途径给予的抗生素的吸收通过使用抗生素与由C6至C18醇的醚和聚氧乙烯二醇组合的双组分吸收增强系统与第二组分一起使用而显着增强选自聚氧乙烯二醇C6至C18甘油酯，C6至C18羧酸或其盐，以及两种或多种C6至C18羧酸的酯，甘油和聚氧乙烯二醇。通常包括载体和佐剂。这些组合物可以以任何方便的口服或直肠剂型施用，包括片剂，胶囊，珠粒和栓剂。

3. 发明授权

US5036102A Method of treating autoimmune diseases comprising administration of psoralen dosage forms 失效
标题翻译：治疗自身免疫疾病的方法，包括给予补骨脂素剂型
公开(公告)号：US5036102A
公开(公告)日：1991-07-30
申请号：US582467
申请日：1990-09-14
申请人： Maria O. Bachynsky , Martin H. Infeld , Richard J. Margolis , Dennis A. Perla
发明人： Maria O. Bachynsky , Martin H. Infeld , Richard J. Margolis , Dennis A. Perla
IPC分类号： A61K9/08 , A61K9/00 , A61K31/365 , A61K47/10 , A61P29/00
CPC分类号： A61K31/365 , A61K47/10 , A61K9/0014 , Y10S514/825 , Y10S514/863 , Y10S514/864 , Y10S514/903 , Y10S514/908
摘要： A method of treating leukocyte mediated autoimmune and skin diseases using psoralen reagent composition comprising sterile aqueous solutions suitable for extracorporeal administration to blood from a subject being treated by ultraviolet-A photophoresis.
摘要翻译：使用补骨脂素试剂组合物治疗白细胞介导的自身免疫和皮肤疾病的方法，其包含适合体外给予受紫外线-A光疗法治疗的受试者的血液的无菌水溶液。

4. 发明授权

US4999375A Psoralen reagent compositions for extracorporeal treatment of blood 失效
标题翻译：用于体外治疗血液的补骨脂素试剂组合物
公开(公告)号：US4999375A
公开(公告)日：1991-03-12
申请号：US336179
申请日：1989-04-11
申请人： Maria O. Bachynsky , Martin H. Infeld , Richard J. Margolis , Dennis A. Perla
发明人： Maria O. Bachynsky , Martin H. Infeld , Richard J. Margolis , Dennis A. Perla
IPC分类号： A61K9/08 , A61K9/00 , A61K31/365 , A61K47/10 , A61P29/00
CPC分类号： A61K31/365 , A61K47/10 , A61K9/0014 , Y10S514/825 , Y10S514/863 , Y10S514/864 , Y10S514/903 , Y10S514/908
摘要： Psoralen compositions for extracorporeal administration to blood prior to reinfusion into a subject comprising a sterile aqueous solution of about 0.005 to about 1 mg/ml of a psoralen ethyl alcohol, propylene glycol and water and having a pH from about 2.0 to about 6.0 are disclosed. These compositions are useful for the therapy of a subject being treated by ultraviolet-A photophoresis.
摘要翻译：公开了在再次输注到受试者之前体外给予血液的补骨脂素组合物，其包含约0.005至约1mg / ml的补骨脂素乙醇，丙二醇和水并且具有约2.0至约6.0的pH的无菌水溶液。这些组合物可用于治疗通过紫外线-A光疗法治疗的受试者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式